PAPERS
Low molecular weight heparin in prevention of perioperative thrombosis A Leizorovicz, M C Haugh, F-R Chapuis, M M Samama, J-P Boissel Abstract Objective-To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence ofthrombosis in patients who have had general or orthopaedic surgery. Design-Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. Subjects-Patients who had had general or orthopaedic surgery. Intetvention-Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. Main outcome measures-Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. Results-The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0-31, 95% confidence interval 0-22 to 0*43; p
Low molecular weight heparin in prevention of perioperative thrombosis A Leizorovicz, M C Haugh, F-R Chapuis, M M Samama, J-P Boissel Abstract Objective-To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence ofthrombosis in patients who have had general or orthopaedic surgery. Design-Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. Subjects-Patients who had had general or orthopaedic surgery. Intetvention-Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. Main outcome measures-Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. Results-The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0-31, 95% confidence interval 0-22 to 0*43; p
